Jazz Pharmaceuticals Plc (JAZZ)
166.93
-0.17
(-0.10%)
USD |
NASDAQ |
Dec 04, 16:00
165.37
-1.56
(-0.93%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.14B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 37.37% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.452 |
| Price to Book Value | 2.562 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.371 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 47.55% |
Profile
| Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland. |
| URL | http://www.jazzpharma.com |
| Investor Relations URL | http://investor.jazzpharma.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland. |
| URL | http://www.jazzpharma.com |
| Investor Relations URL | http://investor.jazzpharma.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |